Physician’s Briefing Weekly Coronavirus Roundup
Adverse Events Rare After BNT162b2 Vaccine in 5- to 11-Year-Olds
Data show 4,249 reports of adverse events after about 8.7 million doses of vaccine were administered; 97.6 percent not serious
BNT162b2 Vaccine Effectiveness 92 Percent for Teens Ages 12 to 17
Estimated vaccine effectiveness of full Pfizer-BioNTech vaccination 92 percent for preventing SARS-CoV-2 infection
Severe Illness, Viral Coinfection Common in Children With COVID-19 Hospitalization
Only one of 272 vaccine-eligible pediatric patients hospitalized with COVID-19 was fully vaccinated
FDA May Allow Pfizer Boosters for 12- to 15-Year-Olds by Monday
Agency also expected to reduce the amount of time adolescents and adults must wait between their second dose of vaccine and booster
Most COVID-19-Related EUAs Not Supported by High-Quality Evidence
Most EUAs were for diagnostic products; most supported by comparisons with previously authorized assays, analytical in vitro studies
Rivaroxaban Improves Clinical Outcomes After COVID-19 Hospitalization
Risk for thrombotic events reduced after 35 days of rivaroxaban compared with no extended thromboprophylaxis
Health Care Workers Had Acceptable Preparedness During First COVID-19 Wave
However, female health care workers had lower preparedness and awareness scores than male counterparts
FDA Says Rapid At-Home COVID-19 Tests Not as Sensitive to Omicron
Agency says that antigen tests 'do detect the omicron variant, but may have reduced sensitivity'
CDC Lowers Estimate of Omicron Prevalence in the United States
Predictions likely to become more accurate as researchers learn more about omicron
